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Abstract 
 
Low oxygen tension is a critical aspect of the metabolic milieu of stem cell 
niches. It has been hypothesized that low oxygen tensions in stem cell niches in vivo 
offer a selective advantage to the maintenance of Hematopoietic Stem Cells (HSC), 
being HSC, but not less immature progenitors, well suited to stand low oxygen 
tensions. It was indeed shown in our laboratory that resistance to severe hypoxia in 
vitro defines hierarchical levels within hematopoietic populations. 
The cancer stem cell (CSC) hypothesis postulates that tumor cells are 
hierarchically organized with respect to tumor growth initiation and maintenance. 
The source of CSC is not entirely clear, and may differ depending on the specific 
disease. Some experimental results are consistent with the idea that CSC can derive 
from normal stem cells that have undergone oncogenic transformation. In contrast, it 
is possible that malignant non-stem progenitor cells acquire the capacity of self-
renewal. In addition, tumors have an elevated rate of glucose uptake and 
consumption through glycolysis, that offers a growth advantage to cancer cells under 
a hypoxic environment. 
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder driven 
by the BCR-Abl oncogenic fusion protein with constitutive kinase activity, which 
drives autonomous cell survival and growth.  
It was also shown in our laboratory that stabilized and cloned leukemia cell lines are 
highly heterogeneous, to comprise cells with a hypoxia-adapted “stem” phenotype as 
well as others with a hypoxia-sensitive “progenitor” phenotype, suggesting that these 
phenotypes are not genetically “frozen”, but flexibly, and reversibly, expressed. 
Thus, leukemia cell lines emerged as suitable models to assess independently the 
sensitivity to chemoterapy of the “stem” or the “progenitor” leukemia cell 
phenotypes to chemotherapy, provided an experimental system capable to select the 
one from the other (such as incubation in hypoxia or in glucose starvation for 
different times) is established. 
BCR-Abl protein suppression emerged as a crucial feature of CML cells 
adaptation to hypoxia. Furthermore, in hypoxia, while surviving leukemia cells are 
generally growth-arrested, Leukemia Stem Cells (LSC) are in large part cycling, 
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indicating that cycling in hypoxia is a specific property of LSC. Thus, hypoxia-
selected LSC, while remaining genetically leukemic, are phenotypically independent 
from BCR-Abl signaling. The suppression of BCR-Abl, molecular target of the 
current CML therapy, combined with the capacity of cycling within the hypoxic 
niches, makes of hypoxia-adapted LSC the most likely candidate to sustain 
treatment-insensitive Minimal Residual Disease (MRD) of CML. 
The main target of this study was to characterize molecular mechanisms 
regulating BCR-Abl expression in blast crisis CML cell lines (K562 and KCL22). 
We found that hypoxia strongly inhibits the overall growth of CML cell populations 
and suppresses both the expression and phosphorylation of BCR-Abl protein and 
transcription of BCR-abl mRNA. These pointed to a dual action of hypoxia as far as 
BCR-Abl expression in concerned, transcriptional and/or post-transcriptional. 
To test whether hypoxia per se is capable of driving the selection of CML cells, 
or it additional environmental/metabolic factors are required, such as glucose 
availability, we maintained cells in normoxia in the absence or the presence of 
glucose for 14 days and compared the data with those obtained in hypoxia: glucose 
shortage reduced cell survival and downregulated BCR-Abl protein but, unlike 
hypoxia, did not affect BCR-abl mRNA levels.  
The effect of environmental/metabolic factors on LSC were determined using the 
Culture Repopulating Ability (CRA) assay, where the time-dependent selection of 
LSC in hypoxic/glucose-starved cultures is estimated following cell transfer to 
secondary standard cultures where the expansion of population is allowed. Results 
allowed us to confirm our hypothesis that energy shortage (hypoxia or glucose 
deprivation) represents the condition selecting LSC cells, BCR-Abl-negative. 
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Introduction 
 
Hematopoiesis and Hematopoietic Stem Cells 
 
The Hierarchy of Hematopoietic Cells 
 
All blood cells are generated from a common hematopoietic stem cell (HSC) 
through an extremely dynamic process called hematopoiesis or blood cell formation.  
The generation of definitive or adult-type HSC during development occurs in the 
aorta-mesonephros-gonad region (AGM) of the embryo, and more recently there 
have been reports that may indicate that definitive HSC are also found in the yolk sac 
and later in placenta. The fetal liver is seeded with HSC from the AGM and they are 
expanded there and generate a large amount of progeny cells. Postnatally, 
hematopoiesis takes place in the BM where the HSCs as well as a complex mix of 
dividing and maturing cells of different lineages can be found.  
The process of hematopoiesis can be described as hierarchical with the rare 
HSCs at the top of the hierarchy giving rise first to progenitors and then to precursors 
with single lineage commitment and ending in terminally differentiated mature cells 
of various lineages. In between the HSC and terminally differentiated cells, there is a 
continuum of progenitors at different stages, which, depending on certain stimuli, 
can divide and progress towards certain lineages (Figure I). It is generally believed 
that hematopoietic development divides at an early stage into a myeloid and a 
lymphoid branch. The lymphoid branch gives rise to B, T and natural killer cells, 
while the myeloid branch differentiates to all other cell types including erythrocytes. 
Indeed, two distinct progenitor populations with either lymphoid or myeloid 
restricted potential, the so-called common lymphoid progenitors (CLP) and common 
myeloid progenitors (CMP), have been isolated from mouse BM.  
HSCs are pluripotent and should therefore be able to give rise to all 
hematopoietic lineages. They are operationally defined as cells that can completely 
reconstitute a recipient following BM ablation. Similarly, they must have the 
capacity to self-renew to give rise to other stem cells. A distinction is often made 
between long-term repopulating HSCs (LT-HSCs) and short-term repopulating HSCs 
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(ST-HSCs). The only way to test these criteria is through BM transplantation 
experiments into lethally irradiated recipients (Larsson J. et al. 2005). 
Although the HSC can only be absolutely defined through BM transplantation 
assays, advances in cell sorting have allowed near purification of murine HSC. 
Early committed progenitor populations, depicted in Figure 1, can also be 
purified. HSC are highly enriched in a population that is negative for lineage markers 
(Lin-) and positive for Sca1 and c-Kit (LSK cells). c-Kit, which is the receptor for 
stem cell factor (SCF), has a wider expression pattern than Sca1, marking most 
multipotent progenitors (MPPs). Sca1 and c-Kit are often used together for positive 
selection of HSCs from Lin- cells. 
The LSK cells contain LT-HSC, ST-HSC and MPPs, which cannot repopulate 
recipients. Further enrichment for LT-HSC has been demonstrated by including 
negative selection for the CD34 marker. Indeed, LSK CD34- cells contain a very 
high proportion of HSCs and isolated single LSK CD34- cells have been transplanted 
and have given full long-term hematopoietic reconstitution. A further separation 
between LT-HSC, ST-HSC and MPP has recently been made by showing that 
repopulating HSC express the thrombopoietin (Tpo) receptor (c-mpl), whereas MPP 
do not, and MPPs express Flt3, whereas pluripotent repopulating HSC do not 
(Bryder D. et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                   Introduction 
Dr. Silvia Bono 
“Energy shortage regulates BCR-Abl expression in Chronic Myeloid Leukemia cells  
via transcriptional/post-transcriptional control”                                             5 
 
Figure I. Model of the hematopoietic developmental hierarchy. Self-renewing HSCs reside at the 
top of the hierarchy, giving rise to a number of multipotent progenitors. Multipotent progenitors give 
rise to oligo-potent progenitors including the CLP, which gives rise to mature B lymphocytes, T 
lymphocytes, and natural killer (NK) cells. The common myeloid progenitor (CMP) gives rise to 
granulocyte-macrophage progenitors, which differentiate into monocytes/macrophages and 
granulocytes, and megakaryocyte/erythrocyte progenitors, which differentiate into megakaryocytes 
and erythrocytes. Both CMPs and CLPs have been proposed to give rise to dendritic cells. The cell 
surface phenotype of many of these cell types is shown for the murine and human systems (Bryder D. 
et al. 2006).  
 
Regulation of Hematopoiesis 
 
HSC behaviour and function are governed by two intimately entangled entities. 
One is the gene expression pattern in the cell and the other is the combination of 
external signals within the hematopietic microenvironment. Transcription factors are 
internal signals that regulate gene expression, while external signals are mediated by 
cell-cell interactions, cell-extracellular matrix (ECM) interactions and soluble growth 
factors. Signals from internal and external regulatory factors decide whether HSCs 
are maintained in quiescence, proliferate, undergo apoptosis, or migrate out of the 
BM space (Larsson J. et al. 2005). 
The acquisition of genetic and epigenetic alterations leads to deregulation of 
these processes, including the onset of uncontrolled growth and the development of 
hematological diseases such as leukaemia (Kennedy A. et al. 2008). Understanding 
the cellular and molecular controls of normal blood cell development makes it 
possible to answer questions about the origin and treatment of these diseases (Sachs 
L. 1996).  
 
The Hematopoietic Stem Cell Niche  
 
Hematopoietic Stem Cells Reside in Bone Marrow Niches 
 
HSCs, which reside in BM, proliferate and differentiate to supply blood 
components to the body. In order to maintain the homeostasis blood homeostasis, 
HSCs are regulated tightly by a specific microenvironment called “stem cell niche”. 
The niche is composed of a vast milieu of cellular and humoral factors. Two different 
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niche environments, called “osteoblastic” and “vascular” niches have been identified 
to alternatively regulate HSC maintenance, clonal expansion and exhaustion. It is 
debated wheter the two different niches are physically separated - or represent 
different states transiently induced in a single niche by competing stimuli. The 
periosteal region of the BM is indeed a complex structure where HSCs are influenced 
not only by osteoblasts but also by vasculature and other stromal structures. 
(Nakamura-Ishizu A. et al. 2013). 
 
Evidence for a Hypoxic Nature of the  
Hematopoietic Stem Cell Niche 
 
While it is widely assumed that direct contact to the supportive osteoblasts and 
stromal cells regulate HSCs within the endosteal niche, the overall nature of the 
environment was found essential for the maintenance and protection of HSCs. 
Considering that BM niches harboring quiescent HSCs are located at distance of 
several cell diameters from blood vessels, such as the thin-walled sinusoids, the 
physiological condition of the niche environment appears to be a relatively low 
oxygen tension and a limited nutrient supply (Eliasson P. et al. 2010).  
The ability to isolate and culture stem cells in vitro has greatly advanced the 
understanding of the role of the niche in some stem cell systems. Like all other cells, 
stem cells were typically cultured under ambient oxygen tensions, with very little 
attention paid to the metabolic milieu of the niche in which they normally resided in 
vivo. This practice led researchers to focus on identifying growth factors and 
signaling proteins, failing to explore the equally important metabolic factors of the 
niche (Scadden D.T. et al. 2006).  
Later, studies carried out by altering oxygen concentrations in the incubation 
atmosphere showed that oxygen tension is a regulator of adult as well as embryonic 
and adult stem cells (Cipolleschi M.G. et al. 1993, Eliasson P. et al. 2010, 
Panchision D.M. et al. 2009, Silvan U. et al. 2009) and fueled the hypothesis that 
low oxygen tension is a critical aspect of the metabolic milieu of stem cell niches 
(Cipolleschi M.G. et al. 1993). Furthermore, the identification of previously 
undescribed stem cells in compartments known to be notoriously hypoxic, as in the 
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case of the kidney medulla/papilla, continues to drive the excitement behind this 
hypothesis (Oliver J.A. et al. 2004). 
Indeed, adult tissues experience a wide range of oxygen tensions that are 
considerably different from the inhaled ambient oxygen tensions of 21% (160 
mmHg) (Figure II). The partial pressure of oxygen (pO2) of inspired air 
progressively decreases after it enters the lungs and as it travels in the blood 
throughout the body. By the time it reaches organs and tissues, pO2 levels have 
dropped to 2%-9% (14–65 mm Hg) (Brahimi-Horn M.C. et al. 2007). This pressure 
is a drastic departure from oxygen tensions in ambient air that are typically 
considered ‘‘normoxic’’ by conventional standards of cell-culture practice. 
It has been hypothesized that low oxygen tensions in stem cell niches offers a 
selective advantage to HSC mainteinance, being HSC, but not less immature 
progenitors, well suited to stand low oxygen tensions (Cipolleschi M.G. et al. 1993). 
Indeed, growing cells that undergo aerobic metabolism are subject to some degree of 
oxidative stress through the generation of reactive oxygen species that can damage 
DNA. This risk is supported by direct evidence that mouse embryonic fibroblasts 
accumulate more mutations and senesce faster when cultured under 20% O2 than 
cells cultured under 3% O2 (Busuttil R.A. et al. 2003). Thus, by residing in 
anatomical compartments at relatively low oxygen tensions (in the range of 1%-9%), 
HSCs may escape this damage together with growth pressure (Figure II).  
In addition, hypoxia has been shown to activate molecular pathways typical of 
stem cells, such as Oct4 and Notch. Finally, oxygen tensions as low as 1% appears to 
decrease proliferation and maintain ESC pluripotency, while higher oxygen tensions 
(3%-5%) appear to maintain pluripotency with no effect on proliferation (Mohyeldin 
A. et al. 2010). 
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Figure II. Oxygen Tension Measurements in Various Stem Cell Compartments. Currently 
available data are reported for hematopoietic, mesenchymal, and neural stem cells in their designated 
niches: the bone marrow, adipose tissue, and the subventricular zone (SVZ), respectively. Red cells 
represent HSCs, MSCs, and NSCs. Although direct measurements from the SVZ have never been 
performed, measurements of oxygen tension as low as 0.55% O2 in various areas of the brain suggest 
that gradients of oxygen may exist in the SVZ (Mohyeldin A. et al. 2010).  
 
Hypoxic Niche for Cancer Stem Cells 
 
The cancer stem cell hypothesis postulates that tumor cells are hierarchically 
organized with respect to tumor growth initiation and maintenance. CSCs, known 
also as tumor-initiating cells, have now been isolated from several human cancers, 
including leukemias, breast, brain melanoma, colon, and pancreatic cancer, and the 
presence of CSC in tumor cell populations correlates strongly with tumor recurrence 
and treatment failure (Mohyeldin A. et al. 2010).  
The characterization of CSC niche and its regulators has been object of intense 
research. Initial reports on CSCs argued for an intimate relationship with tumor 
vasculature, suggesting a perivascular niche like that seen in the Neural Stem Cell 
Niche, NSC (Figure 3) (Calabrese C. et al. 2007).  
Besides the well-established perivascular niche, CSC have recently been 
proposed to reside in a second niche type, further away from vasculature and, as a 
consequence, more hypoxic (Li Z. et al. 2009). Hypoxic microenvironments within 
tumors have long been appreciated to be a product of aberrant vasculature and due to 
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a rapidly dividing tumor mass that outstrips its vascular supply (Figure III) 
(Pouysségur et al. 2006). Zones of necrosis can readily be seen in rapidly dividing 
cancers, and hypoxia has been associated with treatment resistance, local invasion, 
and poor clinical outcome (Keith B. et al. 2007). In addition, the undifferentiated 
phenotype of solid tumors seen often in neuroblastoma, breast, and cervical cancers 
strongly correlates with tumor hypoxia (Mohyeldin A. et al. 2010). 
 
 
 
 
 
 
 
 
 
 
Figure III. Cancer Stem Cell Niche. (Mohyeldin A. et al. 2010) 
 
CSC typically represent a small fraction of the total tumor, can be enriched on 
the basis of cell-surface marker expression, and generate serially transplantable 
tumors in recipient immunodeficient mice. Some CSC also express ABC 
glycoprotein transporters at the cell surface, a trait shared with normal HSC. These 
transporters effectively pump out vital dyes, resulting in a characteristic unlabeled 
“side-population” of cells detected in flow cytometry plots. Unfortunately, these 
transporters also eliminate chemotherapeutic drugs, thereby promoting the multidrug 
resistance (MDR) observed in a large number of cancer cell lines.  
The source of CSC is not entirely clear, and may differ depending on the specific 
disease. Some experimental results are consistent with the idea that CSC can derive 
from normal stem cells that have undergone oncogenic transformation, as described 
for human AML leukemic stem cells (Huntly B.J.P. et al. 2005). In contrast, it is 
possible that malignant progenitor cells, or even differentiated cells, acquire the 
capacity of self-renewal (Krivtsov A.V. et al. 2006). 
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Within the high cell density typical of tumors, the microenvironmental 
restrictions which have just been described produce a fierce clonal competition, in 
which the staminal pool is given an advantage by its resistance to hypoxia. In these 
regions the neoplastic population is continuously exposed to the effects of 
hypoxic/ischemic environments with the following consequences: (a) selection of 
hypoxia-resistant clones, either arising spontaneously in the course of neoplastic 
progression, or driven by hypoxia itself, which is capable of acting as a potent gene 
modulator and is a major source of genetic instability in tumor populations; and (b) 
the creation of hypoxic niches, in which cancer cells selected for their adaptation to 
hypoxia can survive indefinitely in the dormant state, resisting both radio- and 
chemo-therapy. It therefore seems imperative to eradicate these cancer pockets and 
to pursue an active search for treatments attempting to prevent the ultimate 
mechanism of cell adaptation to hypoxia (Olivotto M. et al. 2008). 
 
The predilection of cancer cells for anaerobic glucose 
metabolism  
 
Compared to non-malignant tissues, tumours in general have a high rate of 
glucose uptake accompanied by elevated glucose consumption through glycolysis 
(Gatenby R.A. et al. 2004). In the 1850s, Louis Pasteur showed that aerating yeast, 
a facultative anaerobe, leads to an increase in growth but a decrease in fermentation 
and glucose consumption, the “Pasteur effect”. So for biomass production yeast are 
incubate in oxygenated conditions but for ethanol production oxygen is made 
limiting.  
The initial recognition that cancer cells exhibit atypical metabolic characteristics 
can be traced back to the pioneering work of Otto Warburg over the first half of the 
twentieth century. In the presence of oxygen, most normal tissues metabolize glucose 
to pyruvate through glycolysis, and then completely oxidize a large fraction of the 
generated pyruvate to carbon dioxide in the mitochondria through the tricarboxylic 
acid (TCA) cycle and theoxidative phosphorylation (OxPhos). Under anaerobic 
conditions, normal cells redirect glycolytic pyruvate away from mitochondrial 
oxidation and instead largely reduce it to lactate. The fundamental paradigm 
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stemming from Warburg’s studies was that in contrast to normal cells, tumors 
metabolized glucose to lactate even under aerobic conditions, despite this process 
being by far less efficient: 38 versus 2 ATP molecule per molecule of glucose 
(Figure IV). This seemingly paradoxical phenomenon, called the “Warburg effect”, 
has been observed in several tumor types and often occurs in parallel with a marked 
increase in glucose uptake and consumption (Brahimi-Horn M.C. et al. 2007, 
Cantor J.R. et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
Figure IV. Tumour cells switch from aerobic to anaerobic glucose metabolism despite the lower 
energy yield. Non-malignant and malignant cells take-up glucose from the blood stream via 
membrane glucose transporters (Glut) and metabolize glucose through the glycolytic pathway to form 
pyruvate. Pyruvate in non-malignant cells enters the mitochondrial tricarboxylic acid cycle (TCA) and 
oxygen-requiring oxidative phosphorylation (OxPhos) to produce CO2 and 38 molecules of ATP. In 
contrast malignant cells convert pyruvate to lactic acid to produce two molecules of ATP (Brahimi-
Horn M.C. et al. 2007). 
 
It is only now that the global mechanism behind the cancer cell predilection for 
glucose metabolism to lactic acid is starting to be understood and that the hypoxia-
inducible factors (HIF) are surfacing as one of the major actors. HIF acts basically in 
two ways: promoting anaerobic glucose metabolism and repressing or rendering 
more efficient mitochondrial respiration. The genes coding for certain glucose 
transporters and for enzymes of the glycolytic pathway are among the many genes 
that are directly up-regulated by HIF. The conversion of pyruvate to lactic acid is 
also enhanced by up-regulation of the enzyme lactate dehydrogenase A (LDH-A), 
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the enzyme that catalyses pyruvate conversion to lactic acid (Fantin V.R. et al. 
2006).  
Cancer cells prefer to use aerobic glycolysis for ATP production while still 
retaining the function of OxPhos for the following reasons:  
- Glycolysis is more suitable for cancer growth. Since proliferation of cancer 
tissues is faster than normal tissues, it not only needs energy, but also metabolic 
intermediates for the biosynthesis of macromolecules. Many intermediates from 
glycolysis and the TCA cycle can be used to synthesize macromolecules, such as 
nucleic acids, lipids and proteins, required for cancer growth (Zheng J. 2012). 
- A too efficient productions of ATP (via cell respiration) may not be a good 
thing for cancer cells. If cancer cells use glucose with high efficiency, ADP is 
massively converted to ATP. The high concentration of ATP will inhibit 
phosphofructokinase 1 (PFK1), the rate-limiting enzyme in glycolysis and pyruvate 
kinase 1 (PK1), and glycolysis will be inhibited. Inhibited glycolysis is unfavorable 
for cancer cell growth. Although glycolysis yields less ATP than OxPhos, the speed 
of ATP generation in the former is quicker than in the latter. Generally speaking, 
rapidly proliferating tissues such as cancer and embryonic tissues rely more on 
glycolysis for ATP production, whereas differentiating tissues rely primarily on 
OxPhos (Berridge M.V. et al. 2010, Vander Heiden M.G. et al. 2009).  
- Glycolysis offers a growth advantage to cancer cells under a hypoxic envi-
ronment. Glycolysis produces lactate which is released into the extracellular space, 
leading to an acidic microenvironment which enhances the invasion and metastasis 
of cancer cells (Gatenby R.A. et al. 2008, Vaupel P. 2010).  
- Due to the decrease of mitochondrial OxPhos, less reactive oxygen species 
(ROS) are generated, which are cytotoxic to cancer cells (Zheng J. 2012). 
Increasing evidences show that oncogenes such as Ras and c-Myc, and the 
protein kinase Akt, which promote cell survival are also responsible for the peculiar 
cancer cell metabolism.  
c-Myc was found to induce up-regulation of the glucose transporter GLUT1 and 
several glycolytic enzymes as well as LDH-A.  
The tumour suppressor p53 on the other hand maintains cells in normal aerobic 
mitochondrial metabolism by slowing glycolysis. Regulation of glycolysis occurs 
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though the induction by p53 of the TP53-induced glycolysis and apoptosis regulator 
(TIGAR) gene that decreases the level of fructose-2,6-bisphosphate resulting in 
inhibition of glycolysis and through negative regulation of the glycolytic enzyme 
phosphoglycerate mutase (PGM). 
Repression of pyruvate metabolism through mitochondrial respiration provides a 
mitochondrial bypass mechanism that promotes anaerobic glucose metabolism but 
also spares oxygen. This occurs though HIF activation of the expression of pyruvate 
dehydrogenase kinase 1 (PDK1) that inhibits pyruvate dehydrogenase (PDH), the 
enzyme that converts pyruvate to acetyl-CoA for entry into the TCA cycle. LDH-A 
knockdown not only suppresses lactate production in tumour cells but increases 
oxygen consumption and OxPhos activity, thereby tipping back the 
glycolysis/respiration balance (Brahimi-Horn M.C. et al. 2007). 
 
Chronic Myeloid Leukemia 
 
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder 
characterized by the Philadelphia (Ph) chromosome, which results from t(9;22) 
(q34;q11) balanced reciprocal translocation. The molecular consequence of the Ph 
chromosome is the generation of the BCR-abl oncogene that encodes for the 
chimeric BCR-Abl oncoprotein, with constitutive kinase activity that promotes the 
growth advantage of leukemic cells (Figure V) (Cilloni D. et al. 2012). 
 
 
 
 
 
 
 
 
 
 
Figure V. BCR-Abl translocation in Chronic Myeloid Leukemia. (www.cancer.gov). 
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The deregulated tyrosine kinase activity of BCR-Abl has been shown to be 
necessary and sufficient to maintain the leukemia phenotype of CML (Cilloni D. et 
al. 2012). The constitutive activation of the Abl tyrosine kinase is a primary event in 
the genesis of CML, as shown by the retrovirally mediated insertion of a human 
BCR-abl gene into murine hematopoietic stem cells and the creation of BCR-abl 
transgenic mice (Daley G.Q. et al. 1990). This represents a critical issue in the effort 
to design molecular therapies. 
 
Natural hystory of CML 
 
CML is characterized by biphasic (and sometimes triphasic) course. The disease 
is usually recognized in a relatively indolent chronic phase (CP) that may continue 
for several years. CP inevitably undergoes progression to an “accelerated phase” 
(AP) and then the so-called “blast crisis” (BC), which are distinguished by the 
overproduction of relatively immature cells (Figure VI). In most cases, CP can be 
suppressed with imatinib mesylate (IM), a tyrosine kinase inhibitor (TKI) active on 
the BCR-Abl protein (Cortes J. 2004). 
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Figure VI. Disease progression in Chronic Myeloid Leukemia. In chronic phase (CP), the bulk of 
leukemic stem cells remain capable of undergoing differentiation, leading to the excessive production 
of mature granulocytes. In the advanced disease, differentiation is blocked and disease is sustained by 
the proliferation of immature blasts. Deleterious genetic events (inset) are believed to accumulate 
within stem and progenitor cells of the leukemic clone until there are sufficient secondary mutations 
to drive the transition from chronic phase to advanced disease. These include: an increase in genomic 
instability through interference with genomic surveillance and DNA-repair proteins and a progressive 
telomere shortening. In CP cells essential tumour-suppressor (TS) proteins remain functional and 
allow cells to undergo replicative senescence or apoptosis. However, in advanced phase blasts there is 
evidence that TS function has been lost (Melo J.V. et al. 2007). 
 
However, long interruption or discontinuation of IM treatment is not 
recommended, even in patients with complete molecular remission, because IM does 
not kill quiescent leukemia stem cells (LSC), which thus persist in a majority of 
patients and may cause disease relapse. The resistance to IM that develops in a 
portion of CP patients is most often caused by a mutation in the kinase domain 
abolishing binding of IM to BCR-abl or by the amplification of BCR-abl gene. 
Moreover, advanced-stage CML responds poorly to any therapy including IM. LSC 
are cancer stem cells (CSCs) which are therefore typically characterized by the 
ability to self-renew, thereby representing a cell subset of oncogenic cells capable of 
initiating and propagating disease. Therefore, to cure patients with CML, LSC need 
to be eradicated (Gangemi R. et al. 2009). Hence, immunization against CSC 
markers might be an important method for CSC elimination. In fact, the only long-
lasting remissions of CML are achieved by immunotherapy associated with HSC 
transplantation or IFN-α treatment (Pinilla I.J. et al. 2009). In BC, another type of 
self-renewing cell different from typical LSC has been identified: these cells can be 
defined “staminalized” granulocyte-macrophage progenitors and are responsible for 
the rapid expansion of the blast cell population (Jamieson C.H.M. et al. 2004). 
 
BCR-Abl as a direct cause of genetic damage and instability 
 
During the progression of CML, genomic instability of leukemic cells leads to 
the accumulation of mutations including chromosomal abnormalities found in about 
80% of CML patients. These genetic changes result in the generation of malignant 
cells with activated alternative oncogenic pathways and thus independent of the 
transformation potential of the BCR-Abl protein (Smahel M. 2012).     
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The effects of BCR-Abl on cell signaling have been well documented (Melo 
J.V. et al. 2007). These effects include increased proliferation through the activation 
of ras, increased transcriptional activity via STAT recruitment, decreases in 
apoptosis through activation of PI3K/AKT and changes in adhesion and 
phosphorylation of cytoskeletal proteins. While the contribution of these pathways in 
initiating CML is clear, it is not clear wheter these pathways drive progression from 
chronic-phase to advanced-phase disease (Skorski T. 2002).  
BCR-Abl is believed to cause genomic instability directly. When considering the 
effects of BCR-Abl on genetic instability, one must confront a seeming paradox: cell 
lines with constitutively activated kinases, such as BCR-Abl, accumulate more DNA 
damage than similar cell lines without such a constitutive activation, yet cell lines 
with activated kinases repair DNA damage faster. However, the combination of more 
DNA damage and more repair activity may lead to less exact repair. Furthermore, 
since BCR-Abl also up-regulates antiapoptosis genes bcl-2 and bcl-xL, and thus 
causes G2/M delay, the stage is set to accumulate DNA damage without the 
mechanisms to eliminate these cells (Majsterek I et al. 2002, Slupianek A. et al. 
2002). Bcr-Abl itself can also cause DNA damage by increasing reactive oxygen 
species (ROS); these ROS can lead to DNA base-pair transversions (GC→TA) and 
transitions (GC→AT) (Sattler M. et al. 2000). Taken together, BCR-Abl dependent 
genetic instability may lay the groundwork for chromosomal aberrations, mutations, 
and changes in gene expression that hallmark progression.  
An increase in BCR-Abl level is seen in advanced-phase CML, and this 
increased activity affects several cellular functions. Blast phase is paralleled by an 
increase in both BCR-abl mRNA and protein levels. This increase is not extreme 
(approximately 3-fold) but appears associated with an increase in activation of 
signaling (as evidenced by increased Crkl phosphorylation), and in vitro changes of 
clonality, growth factor independence, proliferation, and block in apoptosis (Barnes 
D.J. et al. 2005, Modi H. et al. 2007). 
Since BCR-Abl level is associated with progression, a logical question is 
whether this phenomenon also plays a role in imatinib resistance, since blast crisis is 
relatively resistant to TKI therapy. However, the relationship of increased BCR-Abl 
levels to imatinib resistance is unclear. The culture of cell lines in the presence of 
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imatinib to induce the development of resistance to the drug led to suggest that 
higher BCR-Abl levels are associated with a shorter time to the development of abl 
point mutations. On the contrary, the use of a model of human CD34+ cells 
transduced with Bcr-Abl led to suggest that high Bcr-Abl expression is associated 
with increased sensitivity to imatinib, suggesting that these cells were “addicted” to 
high levels of BCR-Abl (Barnes D.J. et al. 2005, Modi H. et al. 2007). Of note is 
that the mechanism of increased Bcr-Abl mRNA and protein levels in progressive 
disease is unclear; although some cases of blast crisis have multiple copies of the Ph 
chromosome, such abnormalities are not the rule.  
If BCR-Abl causes genomic instability, it is logical that unchecked BCR-Abl 
will inevitably yield further genomic changes. But why did the Ph chromosome arise 
in the first place? Were there genetic lesions in the stem cell that created poor DNA 
maintenance even before the acquisition of Ph, facilitating the incidence of the 
disease? Two observations suggest a stem cell disorder preceding the acquisition of 
Ph. First, the BCR-abl transcript can be found in the peripheral blood of more than 
25% of normal “older” (>55 years) individuals (Bose S. et al. 1998) Such findings 
could be either from the increased instability associated with aging, or accumulation 
of genotoxic insults over time. The second interesting finding is that clonal 
abnormalities in Ph- cells are seen in approximately 5% of patients with chronic-
phase CML treated with imatinib, despite the maintenance of Complete Cytogenetic 
Response Rate, CCyR (Bumm T. et al. 2003, O’Dwyer M.E. et al. 2003). This 
occurrence suggests that more primitive stem cells, before those acquiring the Ph, 
have some genetic instability, and when imatinib selects against the Ph clone, these 
cells gain a competitive advantage (Radich J.P. 2007). 
 
The functions of the translocation partners 
 
The human abl gene, which is a proto-oncogene with omology to the v-abl 
oncogene carried by the Abelson murine leukemia virus (A-MuLV), has been 
mapped to a region of 225 kb on chromosome 9 and it is expressed as either a 6- or a 
7-kb mRNA transcript, with alternatively spliced first exons, exons 1b and 1a, 
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respectively, spliced to the common exons 2-11. Exon 1b is approximately 200 kb 5’ 
of exon 1a (Chissoe S.L. et al. 1995). 
It encodes a 145-kDa non-receptor tyrosine kinase protein ubiquitously 
expressed, with 2 isoforms arising from alternative splicing of the first exon 
(Deininger M.W.N. et al. 2000). 
The normal Abl protein is distributed in both the nucleus and cytoplasm of cells 
and can shuttle between the two compartments (Ren R. 2005), and it binds 
specifically to DNA, suggesting that this may be critical to its normal biological 
function. In contrast, the chimeric p210 BCR-Abl and other Abl transforming 
proteins are only present in the cytoplasm, and lack the ability to bind DNA 
(Clarkson B. et al. 2003). 
Several structural domains can be defined within the protein (Figure VII). Three 
SRC homology domains (SH1-SH3) are located toward the NH2 terminus. The SH1 
domain carries the tyrosine kinase function, whereas the SH2 and SH3 domains 
allow for interaction with other proteins. Proline-rich sequences in the center of the 
molecule can, in turn, interact with SH3 domains of other proteins, such as Crk. 
Toward the end, nuclear localization signals and the DNA-binding and actin-binding 
motifs are found. 
Several fairly diverse functions have been attributed to Abl, and the emerging 
picture is complex. Thus, the normal Abl protein is involved in the regulation of cell 
cycle, in the cellular response to genotoxic stress, and in the transmission of 
information about the cellular environment through integrin signaling. 
Overall, it appears that the Abl protein serves a complex role as a cellular 
module that integrates signals from various extracellular and intracellular sources 
and that influences decisions relative to cell cycle and apoptosis (Deininger M.W.N. 
et al. 2000).  
Mice with a homozygous disruption of the abl gene -- either through a null 
mutation or a deletion of the carboxy-terminal third of the protein -- are variably 
affected, but phenotypes include an increased incidence of perinatal mortality, 
lymphopaenia and osteoporosis. abl-null mice are also smaller, with abnormal head 
and eye development (Ren R. 2005). 
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Figure VII. Structure of the Abl protein. Two isoforms of Abl (human types 1a and 1b) are 
generated by alternative splicing of the first exon, one of them (1b) contains a myristoylation 
modification site (Myr). Apart from the alternatively spliced sequences, the aminoterminal half of Abl 
contains tandem SRC homology 3 (SH3), SH2 and the tyrosine-kinase (Y-kinase) domains. These 
domains can assemble into an auto-inhibitory structure, in which the SH3 and SH2 domains function 
as a ‘clamp’ that holds the kinase in the ‘off’ state. In Abl1b, the myristoyl group at the extreme end 
of the amino-terminal segment also binds to the tyrosine-kinase domain and functions as a ‘latch’ that 
keeps the SH3–SH2 clamp in place. In its carboxy-terminal region, Abl contains four proline-rich 
SH3 binding sites (PPs), three nuclear localization signals (NLSs), one nuclear exporting signal 
(NES), a DNA-binding domain (DBD), and an actin-binding domain (ABD). This actin-binding 
domain contains binding sites for both monomeric (G) and filamentous (F) forms of actin. The points 
in Abl that fuses with BCR and GAG (for v-Abl) are indicated (Ren R. 2005). 
 
The Breakpoint Cluster Region (BCR) gene maps to a region of about 135 kb on 
chromosome 22 and contains 23 exons. The first intron separating exons 1 and 2 was 
initially shown to span a distance of 68 kb but is now known to include two 
additional exons (an alternative exon 1 and an alternative exon 2).  
Two transcripts, 4.5- and 7.0-kb long, have been found, which apparently encode 
for the same, cytoplasmatic 160-kDa protein that, like Abl, is ubiquitously expressed 
(Laurent E. et al. 2001).  
The 5’ untranslated region of the BCR gene is important because the fusion gene 
created by the Ph translocation is placed under the regulation of the BCR promoter 
(Muller A. et al. 1989, Zhu Q.S. et al. 1990, Shah et al. 1991). A region of ~ 1-kb 
upstream of the transcription start site was demonstrated to be the principle site of 
promoter activity.  
Within this region, a CAAT box (conserved sequence upstream of start point of 
transcription, which is recognized by transcription factors) at position 2644 as well as 
an inverted CAAT sequence at position 2718 have been localized. However, neither 
in vitro nor in vivo studies suggest that these sequences are key factors for 
transcriptional regulation of the BCR gene.  
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There is also a TATA box (conserved sequences in the promoter that specify the 
position at which transcription is initiated) 120 bp downstream of the CAAT box. 
This TATA box, TTTAA, is also accompanied by the consensus sequence TCATCG, 
required for 5’ capping of the transcript. 
DNA footprinting and gel retardation assays have also been used to discover 
potential sites for DNA/protein interaction, which might reflect transcription factor 
activity. Several sites were found including ones containing the consensus sequence 
GGGCCGG (as well as the inverted sequence) for the SP1 transcription factor. A 
unique sequence AGGGCCTCAGTTTCCCAAAAGGCA, for which no binding 
protein is known, was also detected. Deletion of that site (versus other potential 
binding sites) resulted in a significant decrease of promoter activity in BCR-abl-
transfected cells (Zhu Q.S. et al. 1990, Shah N.P. et al. 1991). 
The 5’ untranslated region of the BCR gene is also very rich in GC content, 
which makes up 80% of the nucleotides within this stretch of the DNA (Hariharan 
I.K. et al. 1987, Lifshitz B et al. 1988). Within this GC-rich region is a segment 18 
nucleotides long at sites 2376 to 2393, containing the sequence 
GCGGCGGCGGCGGCGGCG with its inverted repeat 363 bp down-stream. These 
sequences are apt to form secondary stem and loop structures, with a possible role in 
translational regulation (Lifshitz B et al. 1988), and are common to many 
housekeeping genes. Other possible start sites upstream of the normal AUG codon 
have been found; however, these have short open reading frames because there are 
stop codons downstream of these sites. It has been suggested that these short 
transcripts could also play a role in regulating protein translation (Muller A. et al. 
1989). 
At the protein level, several structural motifs can be delineated (Figure VIII). 
The first N-terminal exon encodes a serine-threonine kinase. The only substrates of 
this kinase identified so far are Bap-1, a member of the 14-3-3 family of proteins, 
and possibly BCR itself. A coiled-coil domain at the N-terminus of BCR allows 
dimer formation in vivo. The center of the molecule contains a region with dbl-like 
and pleckstrin-homology (PH) domains, that stimulate the exchange of guanidine 
triphosphate (GTP) for guanidine diphosphate (GDP) on Rho guanidine exchange 
factors, which in turn may activate transcription factors such as NF-kB. The C-
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terminus has GTPase activity for Rac, a small GTPase of the Ras superfamily that 
regulates actin polymerization and the activity of an NADPH oxidase in phagocytic 
cells. In addition, BCR can be phosphorylated on several tyrosine residues, 
especially tyrosine 177, which binds Grb-2, an important adapter molecule involved 
in the activation of the Ras pathway (Deininger M.W.N. et al. 2000). 
BCR-deficient mice develop normally, although their neutrophils have been 
shown to produce excess levels of oxygen metabolites following their activation.  
Depending on the precise breakpoints in the translocation and RNA splicing, 
different forms of BCR-Abl protein with different molecular weights (p185 BCR-
Abl, p210 BCR-Abl and p230 BCR-Abl) can be generated in patients, associated 
with Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and 
a milder form of CML, respectively (Ren R. 2005).  
Three breakpoint regions within the BCR genome are responsible for generating 
the predominant BCR-Abl fusion proteins. The minor breakpoint cluster (m-bcr) 
spans 54-kb and results in an e1a2 7.0 mRNA that generates p190BCR-Abl. The major 
breakpoint cluster (M-bcr) spans 5.8 kb and results in either a b2a2 or b3a2 8.5 kb 
mRNA producing p210BCR-Abl. A third breakpoint located at the 3’ end of the gene 
(µ-bcr) generates a e19a2 9.0 kb mRNA forming p230BCR-Abl (Wong S. et al. 2004). 
 
 
 
 
 
 
 
 
Figure VIII. Structure of the BCR protein. BCR contains a coiled-coil (CC) oligomerization 
domain, a serine/threonine (S/T) kinase domain, a Dbl/CDC24 guanine-nucleotide exchange factor 
homology (DH) domain and a pleckstrin homology (PH) domain, a putative calcium-dependent lipid 
binding site (CaLB) and a RAC guanosine triphosphatase-activating protein (RAC-GAP) domain. 
BCR also contains binding sites for growth factor receptor-bound protein 2 (GRB2) at tyrosine 177 
(Y177), as well as for the GRB10, 14-3-3 and the Abl proteins, through its SH2 domain. p185, p210 
and p230 indicate the points at which BCR most commonly fuses to Abl. The number of amino acids 
in each form are indicated in parentheses (Ren R. 2005). 
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Interaction between BCR and BCR-Abl  
 
In Ph+ cells, BCR-Abl phosphorylates BCR on tyrosine residues (Y177) 
reducing its kinase activity. It is know that the overexpression of BCR in Ph+ cells 
produces a phosphoserine form of BCR, which inhibits the oncogenic effects of 
BCR-Abl (Wu Y. et al. 1999). In fact, BCR becomes resistant to tyrosine 
phosphorylation in BCR-Abl cells when its expression is in molar excess. In this 
condition, the excess of BCR protein is mostly in the phosphoserine form and 
reduces the phosphotyrosine content of BCR-Abl, strongly inhibiting its oncogenic 
activity (Wu Y. et al. 1999, Lin F. et al. 2001). This phosphoserine form of BCR is 
also predominant after overexpression of BCR in soft agar clones of the CML K562, 
a Ph+ cell line, containing an inducible BCR gene. As a consequence, these clones 
have reduced ability to induce extramedullary leukemia (Lin F. et al. 2001).  
On the basis of these results, it has been proposed that the BCR protein plays two 
roles in CML (Figure IX) (Arlinghaus R.B. 2002). In the tyrosine phosphorylated 
form, BCR would be neutralized as an inhibitor of BCR-Abl effects and would serve 
as an important facilitator of BCR-Abl-induced leukemia, possibly in the form of a 
heterotetramer structure with BCR-Abl (McWhirter J.R. et al. 1993). On the other 
hand, in the serine/threonine-phosphorylated form, BCR would function as an 
inhibitor of BCR-Abl oncogenic ability.  
 
 
 
 
 
 
 
 
Figure IX. Model describing the interaction of phosphoserine BCR with the SH2 domain of 
BCR-Abl. The model illustrates a two-step serine phosphorylation process and subsequent 
conformational change of BCR involving serine 354. Following phosphorylation of serine 354, a 
unique structural form of BCR is produced by further serine phosphorylation. This form is identied as 
pSer BCR**. The pSer BCR** structure is proposed to bind to a site within the SH2 domain of the 
Abl sequence causing perturbation of the catalytic domain, which leads to reduced tyrosine kinase 
activity. In essence the data predict a two site model for the SH2 domain. One site binds 
phosphotyrosine, and a second site binds phosphoserine BCR (Arlinghaus R.B. 2002). 
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It has proposed that BCR may play a role in generating the myeloid phenotype 
caused by BCR-Abl in CML patients and may be an important player in the chronic 
phase of CML by down-modulating BCR-Abl. That BCR-Abl expression increases 
that of BCR protein was shown in TonB210 cells, originated from a clone of murine 
IL-3-dependent hematopoietic BaF3 cells, in which BCR-Abl expression is 
controlled by a tetracyclineinducible promoter and BCR is stably transduced by 
lentivirus infection (Perazzona B. 2008). After imatinib treatment of TonB210 cells, 
the levels of BCR-Abl and, surprisingly, of the BCR protein decreased, indicating 
that the tyrosine kinase function of BCR-Abl is required to up-regulate BCR protein 
expression. In addition, withdrawal of doxycycline also reduced BCR-Abl and BCR 
protein levels, confirming that BCR-Abl is required for the increased expression of 
the BCR protein. In BaF3 and 32D cells, BCR was expressed at extremely low 
levels, but the treatment with the proteasome inhibitor calpain inhibitor I restored 
BCR expression. Forced expression of BCR-Abl in BCR-transduced cells restored 
high expression of BCR protein, confirming that BCR-Abl is required for preventing 
degradation of the BCR protein.  
Taken together these findings indicate that BCR-Abl upregulate BCR expression 
by interfering with proteasome-mediated degradation of the BCR protein (Perazzona 
B. 2008). 
 
The BCR-Abl oncogenetic pathway 
 
Abnormal interactions between the BCR-Abl oncoprotein and other cytoplasmic 
molecules lead to the disruption of key cellular processes. Examples include the 
perturbation of the Ras mitogen-activated protein kinase (MAPK) pathway leading to 
increased proliferation, the Janus-activated kinase (JAK)-STAT pathway leading to 
impaired transcriptional activity, and the phosphoinositide 3-kinase (PI3K)/AKT 
pathway resulting in increased apoptosis (Figure X) (Cilloni D. et al. 2012).  
The phosphorylation of BCR Tyr177 is essential for BCR-Abl mediated 
leukemogenesis, and its mutation largely abolishes GRB2 binding and diminishes 
BCR-Abl induced Ras activation (Zhang X. et al. 2001). The latter results from the 
interaction of BCR-Abl with other cytoplasmic proteins, which function as adaptor 
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molecules, thus creating multiprotein signaling complexes. The BCR-Abl/GRB2 
complex recruits Son of Sevenless (SOS), which is constitutively associated with the 
GRB2 SH3 domain. In turn, the BCR-ABL/GRB2/SOS complex stimulates 
conversion of the inactive GDP-bound form of Ras to its active GTP-bound state and 
the activation of the scaffold adapter GRB2-associated binding protein 2. As a 
consequence, the GRB2/GAB2/SOS complex causes constitutive activation of the 
Ras downstream pathway, thereby activating the MAPK ERK1/2, which results in 
abnormal cell proliferation. In addition, this complex activates the PI3K/AKT 
pathway (Ren R. 2005), which promotes survival by suppressing the activity of the 
forkhead O (FOXO) transcription factor, and enhances cell proliferation by inducing 
p27 proteosomal degradation and mTOR activation. In addition, BCR-Abl, through 
PI3K/AKT/FOXO4 and finally through upregulation of mTOR, potently blocks 
important cellular processes, such as autophagy. BCR-Abl may activate PI3K by 
more than one pathway, because Crk and Crkl have also been shown to connect 
BCR-Abl with PI3K (Cilloni D. et al. 2012). Once activated, PI3K activates AKT 
kinase, which serves as a key downstream effector by exerting many cellular effects 
through the phosphorylation of downstream substrates that regulate the apoptotic 
machinery, as Bad, caspase 9, Mdm2, and Ask1, resulting in prolonged survival and 
expansion of the abnormal clone (Franke T.F. et al. 1997). 
Key transcription factors are involved in BCR-Abl signaling. Among these a key 
role is played by STAT1 and STAT5 (Signal Transducer and Activation of 
Transcription), which are constantly active in BCR-Abl positive cell lines and in 
primary cells from CML patients, contributing to the induction of cytokine 
independence. In normal cells, nuclear translocation of STATs occurs exclusively 
after cytokine binding to receptors and is mediated by activation of the receptor-
associated JAK kinases. By contrast, in CML, STATs seem to be activated in a JAK-
independent manner through a direct association of STAT SH2 domains with 
phosphorylated tyrosines on BCR-Abl. Activation of STAT5 is at least in part 
responsible for protection from programmed cell death through the upregulation of 
the antiapoptotic molecule Bcl-xL together with the inactivation of the proapoptotic 
molecule BAD by AKT (Cilloni D. et al. 2012). 
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Another postulated nuclear target of the transforming activity of the BCR-Abl 
protein is the protooncogene Myc, which is expressed at a high level in CML cells. 
Myc activation seems to be independent of the RAS pathway but directly 
upregulated by the Abl SH2 region (Cilloni D. et al. 2012). Several lines of evidence 
indicate that Myc is often overexpressed in blast crisis compared with the chronic 
phase, thus linking Myc to progression. Inhibition of c-Myc in vitro with antisense 
oligonucleotides or dominant-negative constructs can inhibit BCR-Abl 
transformation or leukemogenesis (Sawyers C.L. et al. 1992). 
Despite the seemingly endless expansion of the list of pathways that are 
activated by BCR-Abl, and the increasing complexity that is being revealed in these 
pathways, it seems that all of the transforming functions of BCR-Abl depend on its 
tyrosine kinase activity (Lugo T.G. et al. 1990). This precondition has an incredible 
intrinsic clinical potential with regard to the development of more sophisticated 
targeted therapies. 
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Figure X. Molecular pathways activated by BCR-Abl. The BCR-Abl proteins can form dimers or 
tetramers through their CC domains, and trans-autophosphorylate. Phosphorylation at the Y177 
residue generates a high-affinity binding site for growth factor receptor-bound protein 2 (GRB2). 
GRB2 binds to BCR-Abl through its SH2 domain and binds to SOS and GRB2-associated binding 
protein 2 (GAB2) through its SH3 domains. SOS in turn activates Ras downstream pathway, thereby 
activating MEK1/2 and MAPK and resulting in abnormal cell proliferation. In addiction the complex 
activates the PI3K/AKT pathway (Cilloni D. et al. 2012). 
 
3’UTR mediated gene regulation  
 
Eukaryotic gene expression is controlled at the transcriptional and translational 
levels. After transcription, the messenger RNA (mRNA) is either translated into 
protein or degraded, depending upon its function in the cell. The stability of mRNA 
depends on different regions containing cis-acting elements and trans-regulating 
factors binding directly or indirectly to these cis-acting elements. The formation of 
mRNA-protein complexes followed by a series of re-modelling events, influence the 
translation and decay of mRNAs. These cis-regulatory elements may be located in 
the 5’ untranslated region (UTR), the open reading frame (ORF) or the 3’UTR 
(Figure XI) (Mignone F. et al. 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure XI. Structure of a eukaryotic mRNA. Some post-transcriptional regulatory elements that 
affect gene expression are illustrated. Abbreviations (from 5’ to 3’): UTR, untranslated region; m7G, 
7-methyl-guanosine cap; hairpin, hairpin-like secondary structures; uORF, upstream open reading 
frame; IRES, internal ribosome entry site; CPE, cytoplasmic polyadenylation element; AAUAAA, 
polyadenylation signal (Mignone F. et al. 2002). 
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Control at the 5’ UTR level involves RNA secondary structure such as internal 
ribosome entry site, upstream ORF, 5’-terminal polypyrimidine-rich sequences, and 
the methylation state of the cap structure. In the ORF, a synthesized peptide may 
affect translation efficiency of its own mRNA, while the presence of rare codons 
may cause ribosome pausing during translation. Coding region determinants (CRDs) 
of mRNA instability can also be found in the ORF and target mRNAs for rapid 
degradation by endonucleolytic cleavage (c-myc) or rapid deadenylation and 
degradation (c-fos) (Audic Y. et al. 2004; Hosoda N. et al. 2003; Lopez de Silanes 
I. et al. 2007). 
Although regulatory elements are found in all parts of the mRNA from a 
mechanistic point of view, the 3’ UTR is a place of choice for such elements. Indeed, 
it is likely that the 3’UTR is not scanned by the ribosomes (Poyry T.A. et al. 2004). 
Therefore, any RNA/protein interaction taking place in this region persists through 
translation, enabling regulation to take place at any time. Indeed, many 3’ UTR 
contain regulatory sequences that bind RBPs and sncRNA, resulting in the 
stabilization or destabilization of a given mRNA or its translational activation or 
repression (Lopez de Silanes I. et al. 2007). 
It has been shown that alterations in the 3’UTR of many transiently-expressed 
genes leads to enhanced stability of their mRNAs, leading to gene overexpression 
and oncogenesis (Mayr C. et al. 2007), which points to the role of 3’UTR in gene 
expression. 
There are several recognised motifs in 3’UTRs that could be crucial for the 
regulation of mRNAs: the iron response element (IRE), that stabilises transferrin 
receptor (TFR) mRNA when the intracellular iron concentration is low, resulting in 
iron uptake, and the most commonly found AU-rich element (ARE) (Lopez de 
Silanes I. et al. 2007). Moreover, in the last few years, there is mounting evidence 
that the 3’UTR of several mRNAs harbour binding sites for microRNA, a class of 
small noncoding RNAs that regulate gene expression. 
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AU-rich elements in the 3’UTR 
 
Adenylate/uridylate rich elements or AREs are the highly conserved elements 
found in the 3’UTR of many mRNAs that code for proto-oncogenes, cytokines and 
nuclear transcription factors (Chen C.Y. et al. 1995) and function as elements that 
are important for mRNA stability. 10% of human mRNAs are reported to contain 
AREs in their 3’UTR.  
The first direct evidence that the ARE can function as a potent mRNA 
destabilizing element came from a study by Shaw and Kamen in 1986. The stability 
of β-globin mRNA was reduced considerably by inserting a conserved region of 51 
nucleotides containing AUUUA motifs from the 3’UTR of human granulocyte-
macrophage colony-stimulating factor (GM-CSF) into its 3’UTR (Shaw G. et al. 
1986). Later, the mRNA degradation of c-fos, c-myc, β-interferon and many more 
genes was also shown to be the effect of AREs in their respective 3’UTR (Chen 
C.Y. et al. 1994; Chen C.Y. and Shyu A.B. 1994; Jones T.R. et al. 1987; Peppel 
K. et al. 1991).  
AREs are proposed to be of three types, class I and II AREs containing various 
repeats of AUUUA signature motifs and class III lacking this pentamer (Xu N. et al. 
1997). There appears to be a sequence hierarchy by which the three classes of AREs 
are composed from several key sequence features. AREs classified as class I are 
found in early-response gene mRNAs that encode various transcription factors and 
mRNAs for some cytokines like IL-4, IL-6. They contain one to three copies of 
AUUUA motifs coupled with nearby U-rich sequences. Each of these sequence 
features plays a distinct role and together they determine the destabilizing potency of 
the class I AREs (Chen C.Y. et al. 1994). Class II AREs possess multiple repeats of 
the AUUUA pentamer clustered together and the class III AREs contain only a 
couple of U stretches and a U-rich domain. The class II AREs direct asynchronous 
cytoplasmic deadenylation which is consistent with a processive ribonucleolytic 
digestion of polyA tails whereas class I and AUUUA less class III AREs mediate 
synchronous polyA shortening followed by the decay of the mRNA. Existence of 
cross-talk between the AREs and the 3’ end polyA tail dictates the kinetics of 
cytoplasmic deadenylation and thereby the fate of the corresponding mRNA (Xu N. 
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et al. 1997). The length of AREs, especially the number of overlapping pentamers 
may also contribute to mRNA half-life (Akashi M. et al. 1994).  
 
Regulation of ARE-gene expression: RNA binding proteins 
 
The mechanisms through which AU-rich RNA binding proteins (AUBP) mediate 
post-transcriptional regulation, particularly in the context of immune regulation and 
the inflammatory response, have been reviewed extensively (Stumpo D.J. et al. 
2010, Gruber A.R. et al. 2011, Baou M. et al. 2009, Khabar K.S. 2009, Anderson 
P 2010, von Roretz et al. 2008). Most AUBP function as accessory proteins to 
recruit mRNAs and to regulate their fate in various sub-cellular compartments, such 
as the exosome mediating 3’-5’ decay, processing bodies for 5’-3’ decay and stress 
granules for translational arrest. Some AUBP function cooperatively or 
antagonistically with each other or with argonaut (AGO) endoribonucleases within 
RNA-induced silencing complexes (RISC) mediating miRNA-dependent decay 
(Anderson P. 2010, von Roretz C. et al. 2008). 
Three distinct types of AUBP (ARE poly-U-binding degradation factor-1/AUF1, 
Hu antigen/HuR/HuA/ELAVL1 and the tristetraprolin/ZFP36 family of proteins) are 
essential for normal hematopoiesis. Together with two further AU-rich RNA binding 
proteins, nucleolin and KHSRP/KSRP, the functions of these proteins are intimately 
associated with pathways that are dysregulated in various hematopoietic 
malignancies (Baou M. et al. 2011).  
Among these, HuR play a wide role in leukemogenesis. Indeed, it is over-
expressed in M4 Acute Myeloid Leukemia (AML) and correlated with high levels of 
elF4E (Topisirovic I. et al. 2009). It is also overexpressed in acute phase and blast 
crisis in CML as compared to chronic phase disease, with its expression increasing 
progressively during transit from chronic phase to blast crisis (Radich J.P. et al. 
2006). In B-cell Chronic Lymphocytic Leukemia (BCLL), HuR mRNA is 
differentially expressed between cases with high and low levels of miR-16/miR-15 
(Calin G.A. et al. 2008) consistent with its mRNA being targeted by miR-16 (Xu F. 
et al. 2010). Thus more emphasis on this protein is given throughout this work. 
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Results 
 
Hypoxia reduces CML cell population expansion  
 
The K562 and KCL22 stabilized cell lines were used, the first one isolated from 
BM and the others from pleural effusion of patients with CML in blast crisis. 
Thereby, both cell lines exhibit a highly undifferentiated, lymphoblast-like, 
phenotype. 
Figure 1 shows the kinetics of the total number of viable cells in K562 and 
KCL22 cultures incubated for 7 days in severe hypoxia (0.1% O2). Cell number 
increased over the first 2 or 3 days of incubation, respectively, in K562 and KCL22 
cell cultures, and then decreased to reach, at day 7, about one tenth for K562 cells 
and one third for KCL22 cells with respect to the time-zero value. Thus, KCL22 cells 
resulted less sensitive to the effect of incubation in hypoxia. 
These results led us to hypothesize that the different behavior of the two cell 
lines, although both derived from patients in blast crisis, may reflect differences in 
the mechanisms of regulation of BCR-Abl. 
 
Hypoxia suppresses BCR-Abl protein expression 
 
The expression levels of BCR-Abl protein and its phosphorylated form were 
determined by Western blotting in K562 and KCL22 cells during incubation in 
hypoxia.  
Figure 2 shows that BCR-Abl protein remained more or less unchanged over the 
first 2 o 3 days of incubation, respectively, in K562 or KCL22 cells, while prolonged 
hypoxia led to the complete suppression of protein in both cell lines. 
The complete removal of BCR-Abl protein in hypoxia suggests that its 
expression may be detrimental to the cell viability and growth in hypoxia. 
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Figure 1. Effects of severe hypoxia on CML cell number and viability. Exponentially-growing 
K562 (A) and KCL22 (B) cells were plated at 3x105/mL and incubated in hypoxia (0.1% O2) until day 
7; viable cells were counted by trypan blue exclusion at the indicated times. Data represent the Mean 
± SD of four indipendent experiments.  
 
Hypoxia reduces BCR-abl mRNA 
 
To verify whether BCR-Abl protein suppression was associated with a reduction 
of BCR-abl mRNA, its levels were monitored daily during the incubation of K562 
and KCL22 cells in hypoxia (Figure 3). Like in the case of BCR-Abl protein, BCR-
abl mRNA was reduced in both cell lines. This reduction was more marked in K562 
cells, where already after 24h of hypoxia mRNA levels were close to 50% of the 
time-zero value, to continue to decrease significantly during following incubation. In 
KCL22 cells, the reduction was of about 40% after 24h of hypoxia and this value 
was maintained more or less unchanged for the rest of time-course.  
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Figure 2. Effects of hypoxia on BCR-Abl expression and phosphorylation. Exponentially-growing 
K562 (A) and KCL22 (B) cells were incubated in hypoxia for the indicated times. Cell lysates in 
Laemmli buffer were subjected to SDS-PAGE and blotted with antibodies to BCR-Abl and its 
phosphorylated form pBCR-Abl, and with anti-α-Tubulin as loading control. The histograms represent 
the data obtained from the densitometry of bands in blots of three indipendent experiments (Mean + 
SD) and are expressed as the ratio of phosphoBCR-Abl (left) or BCR-Abl to α-Tubulin (right). 
Statistical analysis was performed by paired Student’s t-test. **p ≤ 0.01 vs T0, *p ≤ 0.05 vs T0 
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Figure 3. Effects of hypoxia on BCR-abl mRNA. Exponentially-growing K562 (A) and KCL22 (B) 
cells were incubated in hypoxia for the indicated times. Total RNA was isolated using TRIzol and 
retro-transcribed. BCR-abl mRNA levels were normalized with respect to GAPDH mRNA or to 18S 
rRNA (data not shown) and determined by quantitative Real Time-PCR. Data represent Mean + SD of 
three indipendent experiments: **p ≤ 0.01 vs T0, *p ≤ 0.05 vs T0, # p ≤ 0.01 vs day1, day2, and day4 
 
Different effects of hypoxia on BCR-abl mRNA stability  
 
To investigate on whether the decrease of BCR-abl mRNA in hypoxia (Figure 
3) could be attributed to reduced transcriptional activity or to regulation of mRNA 
stability, we incubated K562 and KCL22 cells under normoxia or for 24 hours in 
hypoxia before blocking transcription by adding of actinomycin D (5 μg/mL) for the 
indicated times. 
K562 cells exhibited comparable BCR-abl mRNA stability (t1/2 = 3.8 hours, R
2 = 
0.7971) in normoxia and in hypoxia. In contrast, in KCL22 cells, the half-life of 
BCR-abl mRNA was significantly reduced in hypoxia compared to normoxia to 4.5 
hours, R2 = 0.805, vs 6.3 hours, R2 = 0.9665, respectively (Figure 4). 
                                                                                                                                           Results 
Dr. Silvia Bono 
“Energy shortage regulates BCR-Abl expression in Chronic Myeloid Leukemia cells  
via transcriptional/post-transcriptional control”                                             34 
 
These results led us to hypothesize that BCR-abl mRNA levels are subjected to 
transcriptional control in K562 cells, to post-transcriptional control in KCL22 cells 
(although we cannot exclude also the involvment of a transcriptional control). 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 4. BCR-abl mRNA stability after the treatment with the transcription inhibitor 
Actinomycin D. K562 (A) and KCL22 (B) cells were exposed to normoxia or for 24 h to hypoxia and 
then transcription was blocked by the addition of actinomycin D (5 µg/mL) for the indicated times. 
BCR-abl and GAPDH mRNA were determined by quantitative Real Time-PCR. The ratios of BCR-
abl to GAPDH mRNA at time-zero in normoxia or after 24 hours of hypoxia were set to 100. The 
transcript levels are reported as percentages of total transcript present at time-zero. The half-life of the 
BCR-abl mRNA was calculated by regression analyses. Data represent Mean ± SD of three 
indipendent experiments: *p ≤ 0.05 HYPOXIA vs NORMOXIA  
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BCR promoter activity 
 
To assess the potential involvement of the transcriptional machinery in the 
regulation of BCR-abl mRNA levels in hypoxia, we transiently transfected K562 
cells with a luciferase reporter vector carrying the BCR promoter (Marega M. et al. 
2010), involved in the activation of both BCR and BCR-abl transcription and we 
performed a gene report assay to compare hypoxic and normoxic cultures (Figure 5). 
Differently from what expected from the clear and progressive suppression of the 
BCR-Abl protein, we did not observe a significant decrease of the transcriptional 
activity of BCR promoter in hypoxia. 
These data indicated that probably BCR-abl transcription in CML cells subjected 
to prolonged hypoxia is not regulated at the promoter level, but rather by other 
mechanisms (for instance, by transcriptional repressors) acting on signal sequences 
that are located far from the BCR promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. BCR promoter activity. A Firefly luciferase reporter construct containing either the BCR 
promoter or the pGL3 basic empty vector was transiently transfected into K562 cells. Cells were 
incubated in normoxia or hypoxia and luciferase activity was measured after 24, 48, and 72h from 
transfection. The ratio of pGL3-luc/BCR to pGL3-luc/empty luciferase activity under normoxia was 
set as 100 for each time point. Data represent Mean + SD of three indipendent experiments. 
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Glucose availability influences CML cell survival and 
downregulates BCR-Abl protein 
 
To test whether hypoxia per se is capable of driving the effects shown above or 
additional environmental/metabolic factors are required, such as glucose availability, 
K562 and KCL22 cells were incubated in normoxia or hypoxia and in the absence or 
the presence of glucose for 14 days.  
As shown in Figure 6, cells maintained in hypoxia without glucose underwent a 
sharp increase of mortality, while cells grown in hypoxia with glucose, behaved as 
expected and described above. In cells incubated in normoxia without glucose, 
compared to cells maintained under standard conditions (normoxia with glucose), it 
is worth noting that under mild restriction of energy supply (normoxia without 
glucose or hypoxia with glucose) the time-course is identical until day 2 (K562 cells) 
or day 3 (KCL22 cells), the days of incubation which precede BCR-Abl protein 
suppression (see Figure 2A and B). Beyond these incubation times, the number of 
viable cells decreases more rapidly in hypoxia w/ glucose than in normoxia w/o 
glucose, likely due to the Pasteur effect. 
 
To deepen the above issue, trying to understand whether there is a correlation 
between cell survival in the absence of glucose and the expression of the BCR-Abl 
protein, we determined this expression by Western blotting in K562 and KCL22 cells 
incubated in normoxia w/o glucose (Figure 7). As can be seen, cells cultured under 
normoxia in the absence of glucose, as well as cells maintained in hypoxia with 
glucose, showed that the time of BCR-Abl protein down-regulation coincides with 
that at which cell survival also starts to decrease. 
These results led to conclude that survival of bulk of leukemia cell population 
depends on the expression of BCR-Abl. 
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Figure 6. Glucose starvation influences cell survival. Exponentially-growing K562 (A) and KCL22 
(B) cells were incubated in normoxia w/ or w/o glucose and in hypoxia w/ or w/o glucose and, at the 
indicated times, viable cells were counted by trypan blue exclusion. Data represent Mean ± SD of four 
indipendent experiments. 
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Figure 7. Glucose starvation inhibits BCR-Abl protein activity by inducing its down-regulation. 
Exponentially-growing K562 (A) and KCL22 (B) cells (3x105 cells/mL each) were incubated under 
normoxia w/o glucose for 9 days. Each day cells were harvested, and the expression of BCR-Abl and 
pBCR-Abl were determined by Western blot. α-Tubulin was blotted as a protein-loading control. The 
histograms represent data obtained by densitometry from three indipendent experiments (Mean + SD) 
and are expressed as the ratio between phosphoBCR-Abl (left) or BCR-Abl (right) to α-Tubulin. 
Statistical analysis was performed by paired Student’s t-test. *p ≤ 0.05 vs T0 
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Glucose deprivation does not affect BCR-abl mRNA levels 
 
To verify whether, under glucose starvation, suppression of BCR-Abl protein 
was associated with that of BCR-abl mRNA, mRNA levels were determined during 
incubation in normoxia w/o glucose in K562 and KCL22 cells (Figure 8).  
BCR-abl mRNA levels were unchanged across incubation in both cell lines, 
leading us to hypothesize a possible post-transcriptional control, translational and/or 
post-translational for cells incubated in normoxia, despite the energy shortage. 
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Figure 8. Effects of glucose starvation on BCR-abl mRNA. Exponentially-growing K562 (A) and 
KCL22 (B) cells were incubated in normoxia w/o glucose for the indicated times. Total RNA was 
isolated using TRIzol and reverse transcribed. BCR-abl mRNA levels were normalized to GAPDH 
mRNA or to 18S rRNA (data not shown) as determined by quantitative Real Time-PCR. Data 
represent Mean + SD of three indipendent experiments. 
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RNA-binding proteins involvment in BCR-Abl post-
transcriptional control 
 
Recent data demonstrate the involvement of different classes of RNA-binding 
protein in normal hematopoiesis and leukemogenesis (Baou M. et al. 2011) In 
particular, the RNA binding protein HuR appears to be overexpressed in blast crisis 
Chronic Myeloid Leukemia (CML) compared with chronic-phase disease with the 
level of expression increasing progressively during transit from the chronic phase to 
the blast crisis (Radich J.P. et al. 2006). HuR is known to play an important role in 
both the stabilization of many mRNAs both in the modulation of translational 
efficiency of different mRNAs. 
We determined the HuR protein levels in K562 and KCL22 cells subjected to 7 
days of hypoxia with glucose or 9 days of normoxia under glucose starvation, to 
evaluate whether HuR could be involved in BCR-Abl translational control (Figure 
9).  
HuR protein levels remained unchanged both in hypoxia and under glucose 
starvation. So, probably, HuR is not responsible for the decrease of BCR-Abl protein 
in these conditions. 
 
Energy shortage does not affect BCR-Abl protein half-life  
 
As reported by Bartholomeusz G.A. et al. 2007, BCR-Abl protein half-life in 
CML cells is approximately 40 hours. We wanted to determine whether hypoxia or 
glucose starvation could interfere with protein decay. K562 and KCL22 cells were 
incubated in normoxia or for 24 hours in normoxia without glucose or hypoxia with 
glucose before blocking translation by the addition of cycloheximide (50 μM) for the 
indicated times (Figure 10). 
No significant differences in the BCR-Abl protein half-life were observed 
between mild energy shortage conditions (hypoxia w/ glucose or normoxia w/o 
glucose) and standard cultures conditions (normoxia w/ glucose).  
These results strenghten the hypothesis of the involvment of translational control 
mechanisms in the BCR-Abl protein expression control. 
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Figure 9. Levels of HuR protein under oxygen or glucose deprivation. Exponentially-growing 
K562 (A) and KCL22 (B) cells were incubated for the indicated times in hypoxia w/ glucose (left) or 
in normoxia w/o glucose (right). Cell lysates in Laemmli buffer were subjected to SDS-PAGE and 
blotting with antibodies raised against HuR, or Vinculin as loading control. The histograms represent 
densitometry data and are expressed as the ratio between HuR and Vinculin in three indipendent 
experiments (Mean + SD). Statistical analysis was performed by paired Student’s t-test.  
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Figure 10. Effects of hypoxia and glucose starvation on BCR-Abl protein half-life. K562 (A) and 
KCL22 (B) cells were exposed to normoxia or for 24 h to hypoxia w/ glucose or normoxia w/o 
glucose. Subsequently, translation was blocked by addition of cycloheximide (50 µM) for the times 
indicated. BCR-Abl protein levels were determined by Western blotting. The ratios of BCR-Abl to α-
Tubulin at T0 in normoxia or after 24 hours of hypoxia w/ glucose or normoxia w/o glucose were set 
to 100. The protein levels are reported as percentages of total protein present at time-zero. The slope 
of the decay line was calculated by standard linear regression, and the BCR-Abl protein half-life was 
determined accordingly. For K562 cells BCR-Abl t1/2 = 78 hours, R2 = 0.9678 (NX - w/ glucose), t1/2 = 
54 hours, R2 = 0.9727 (HX - w/ glucose), t1/2 = 40 hours, R2 = 0.6984 (NX - w/o glucose); for KCL22 
cells, BCR-Abl t1/2 = 44 hours, R2 = 0.8152 (NX - w/ glucose), t1/2 = 48 hours, R2 = 0.7859 (HX - w/ 
glucose), t1/2 = 34 hours, R2 = 0.964 (NX - w/o glucose). Data represent Mean ± SD of three 
indipendent experiments. 
 
Effects of hypoxia and glucose starvation on the 
maintenance of Leukemic Stem Cells  
 
To identify the CSCs, we developed in our laboratory the Culture Repopulating 
Ability (CRA) assay. As mentioned before, this method estimates the culture-
repopulating power of normal or leukemic cells undergoing a selection treatment in a 
primary liquid culture (LC1) by means of their wash and transfer in fresh medium to 
non-selective conditions in a secondary culture (LC2).  
Stabilized leukemia cell lines, ensuring genetically homogeneous cells and 
enhancing repeatability of results, were found nevertheless phenotypically 
heterogeneous, comprising cell subsets exhibiting functional phenotypes of stem or 
progenitor cells. These subsets can be assayed separately, provided an experimental 
system capable to select one from another. On this basis, K562 and KCL22 cells 
were incubated in hypoxia for 7-10 days or in normoxia without glucose for 10-14 
days (selective LC1) depending on the cell line, and after transferred to a normoxic 
non-selective LC2 (with glucose) culture for the indicated times. 
As can be observed in Figure 11, both K562 cells that KCL22 showed a similar 
peak of LC2 repopulation to that we have seen previously (Tanturli M. et al. 2011) 
for Leukemic Stem Cells (LSCs) phenotype (at about 21-24 days of LC2). 
These results confirm the hypothesis that is therefore energy shortage (hypoxia 
as well as glucose deprivation) the driving force to ‘select’ and allow the 
mainteinance of LSCs. 
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Figure 11. Kinetics of LC2 repopulation of hypoxia- or glucose starvation-selected CML cells. 
Exponentially-growing K562 (A) and KCL22 (B) cells were incubated for the indicated times in 
hypoxia w/ glucose or normoxia w/o glucose and then transferred at 3x104 cells/mL to LC2. LC2 were 
incubated in air and viable cells were counted by trypan blue exclusion. Data represent Mean ± SD of 
three indipendent experiments. 
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Discussion  
 
The results of the study presented here suggest that the suppression of BCR-Abl 
protein is a distinctive feature of CML cells adapted to energy shortage. This 
suppression heavily affects the natural history of disease, as it represents the crucial 
condition for the selection of BCR-Abl protein-negative LSC of CML.  
The characterization of molecular mechanisms regulating BCR-Abl expression 
was undertaken using the blast crisis CML cell lines K562 and KCL22. We initially 
showed that incubation of CML cells in hypoxia, results in complete suppression of 
BCR-Abl protein, thereby inhibiting theirs growth. We then demonstrated that also 
BCR-abl mRNA is down-regulated during incubation in hypoxia.  
To investigate if these findings could be due to differences in mRNA stability, 
BCR-abl mRNA half-life was determined. No significant differences in BCR-abl 
mRNA stability could be detected in K562 cells subjected to hypoxia compared to 
those incubated in normoxia. By contrast, in KCL22 cells the half-life of BCR-abl 
mRNA was significantly reduced in hypoxia compared to normoxia. These results 
led us to hypothesize that BCR-Abl suppression in hypoxia follows different 
pathways depending on the cell population considered, being subjected to 
transcriptional control in K562 cells and likely to post-transcriptional control in 
KCL22 cells. 
To further characterize the possible transcriptional control mechanism, we 
focused our attention on the BCR promoter, which regulates the expression of both 
BCR and BCR-abl.  
To test whether there were differences as for BCR-abl transcript in hypoxia 
compared to normoxia, we transiently transfected K562 cells with a luciferase 
reporter vector carrying the BCR promoter. Unexpectedly, the results of luciferase 
assay did not show a significant decrease in the transcriptional activity of BCR 
promoter in hypoxia. Thus, these results suggest that BCR-abl transcription in CML 
cells incubated in hypoxia is not regulated at the promoter level, but rather by other 
mechanisms (for instance, by transcriptional repressors) acting on signal sequences 
that are located far from the BCR promoter.  
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BCR-abl activates glucose metabolism as part of its transforming activity. 
Activation of glycolysis in Ph+ cells is associated with an increase of GLUT-1 
glucose transporter at cell surface and suppression of p53 (Barger J.F. et al. 2013). 
We therefore investigated on the metabolic effects of glucose starvation on BCR-
Abl expression. To test whether hypoxia per se is capable of driving the effects 
shown above or additional environmental/metabolic factors such as glucose 
availability are required, K562 and KCL22 cells were incubated in normoxia or 
hypoxia and in the absence or the presence of glucose. Results showed that cells 
incubated in normoxia in the absence of glucose, as well as those maintained in 
hypoxia in the presence of glucose, undergo a significant decrease of viability and 
suppression of BCR-Abl protein, but not mRNA. This allows to hypothesize the 
involvment of post-transcriptional control, translational and/or post-translational. 
Accumulating data demonstrated the involvement of different classes of RNA-
binding protein in normal hematopoiesis and leukemogenesis (Baou M. et al. 2011) 
In particular, the RNA binding protein HuR appears to be overexpressed in blast 
crisis CML with the level of expression increasing progressively during transit from 
chronic phase to blast crisis (Radich J.P. et al. 2006). HuR is known to play an 
important role in both the stabilization and the modulation of translational efficiency 
of different mRNA. 
We, therefore, evaluated by western blotting the expression levels of HuR in our 
experimental settings. In contrast with what expected, we did not observe significant 
changes of HuR protein level either in hypoxia with glucose or in normoxia without 
glucose. This means that HuR is unlikely to be one of the AUBP responsible for 
BCR-Abl protein suppression under energy shortage conditions. 
The relationship of the level of protein synthesized to that of the corresponding 
mRNA is regulated by translation efficiency and the stability of the synthesized 
protein. In general, it is expected that increases of mRNA levels would result in 
concomitant increases of the corresponding protein. Deviations from this simple 
relationship during changes in gene expression may be due to translational control 
mechanisms, or could result from variations of translation efficiency of alternative 
mRNA isoforms (Stevens G. et al. 2013). 
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Thus, we determined BCR-Abl protein stability in K562 and KCL22 incubated 
in normoxia or hypoxia with or without glucose, to estimate if hypoxia or glucose 
starvation could interfere with protein decay. The results showed no significant 
differences in BCR-Abl protein half-life in any condition. This further confirms a 
key role of translational control in BCR-Abl expression. 
It was previously shown in our laboratory that different types of leukemias 
contain hypoxia-resistant cells exhibiting stem cell properties, as well as less 
immature cells the numerical expansion of which is inhibited in hypoxia and glucose 
shortage. The existence of different, metabolically-characterized, functional cell 
subsets within leukemia cell populations reflects the organization of normal 
hematopoiesis, where the regulatory role of glycolysis and respiration within the 
stem/progenitor cell hierarchy has been long known. Such an organization is 
functional to the maintenance of stem cells within restricted, “metabolically-defined” 
bone marrow areas which we called the “hypoxic” or “ischemic” stem cell niches 
(Giuntoli S. et al. 2011, Cipolleschi M.G. et al. 2013, Rovida E. et al. 2014). LSC 
selected under these conditions remain genotypically leukemic (BCR-abl-positive), 
but phenotypically BCR-Abl-negative (and indipendent of BCR-Abl signaling), a 
feature which makes of these LSC ideal candidates to represent the main CML cell 
subset resistant to IM and responsible for Minimal Residual Disease of CML. 
To address the question wheter hypoxia or glucose starvation might select LSC, 
CML incubated in the absence of glucose for 14 days (LC1), were transferred at 
different times to non-selective secondary cultures (LC2) to estimate the 
maintenance of LSC/LPC potential in LC1 by CRA assay. The fact that LC2 
established with cells rescued from LC1 incubated either in hypoxia or under glucose 
starvation showed a similar kinetics of repopulation, with a peak at days 21-24, 
confirmed our hypothesis that energy shortage (hypoxia or glucose deprivation) 
‘selected’ and maintained LSC. Hypoxia, indeed, which is characterized by a high 
rate of glucose consumption, only accelerates cells selection. 
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Perspectives 
 
The data reported in this thesis, addressing the regulation of BCR-Abl expression 
in blast crisis-CML cell lines, provide a useful background for the elucidation of the 
molecular mechanisms of BCR-Abl suppression and thereby induction of primary 
resistance (refractoriness) of CML cells to therapy. Possible avenues of future work 
in this field are discussed below. 
 
Identification of possible regulatory elements involved in 
BCR-abl transcriptional control in hypoxia 
 
One of the mechanisms through which protein levels in the cell are controlled is 
transcriptional regulation. Certain DNA regions, called cis-regulatory elements, are 
footprints for trans-acting proteins involved in transcription, either for the 
positioning of the basic transcriptional machinery or for the regulation. The basic 
transcriptional machinery is constituted of the DNA-dependent RNA polymerase 
(RNAP), which synthesizes various types of RNA. Core promoters on the DNA are 
used to position the RNAP. Other nearby regions regulate transcription: in eukaryotic 
organisms, in fact, proximal promoter regions, enhancers, silencers, and insulators 
are present (Riethoven J.J. 2010).  
As showed above, BCR-abl gene seems to be subjected to transcriptional control 
in K562 cell line in hypoxia. However, the luminometric assay used in this thesis 
allows to investigate only what happens at the level of BCR promoter. Thus, many 
regulation and binding events may have remained undetected in these experiments. 
To facilitate the identification of all possible binding sites within or outside the BCR 
promoter regions, alternative methods should be employed. Tiling arrays covering a 
broader region of a particular gene locus of interest, or whole-genome tiling arrays 
could be used to study the binding outside the promoter region (Horak C.E. et al. 
2002; Lee T.I. et al. 2006). With the development of next generation sequencing 
technologies, ChIP-seq could be performed for whole genome to map the binding 
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sites in an unbiased manner (Barski A. et al., 2007; Johnson D.S. et al.,2007; 
Schones D.E. et al., 2008).   
 
Functional assays for the putative BCR-abl silencer  
 
The identification of regions possibly exerting a negative control could give us 
the opportunity to further characterize the regulation of BCR-abl fusion gene. So, to 
determine whether the negative control region could act as a silencer, the next step 
could include a functional assay of these sequences, via their sub-cloning in a high 
expression plasmid, in different positions and orientations and fused, for example, to 
the bacterial CAT gene. These plasmids will be transfected into K562 cells, and CAT 
activity determined. 
 
Investigations of histone modifications associated with 
BCR-abl gene regulation machinery 
 
Another component of a transcription regulatory network is the chromatin 
domains and the modifications associated. Chromatin structure affects the binding of 
either sequence-specific or general transcription factors to regulatory elements, thus 
playing a crucial role in the transcriptional regulation of target genes. As a result, 
integrating the information for chromatin modifications and binding of transcription 
factors could facilitate a more complete understanding of transcription machinery 
and regulation. 
Histone lysine acetylation has been shown to be associated with active 
transcription whereas deacetylation correlates with repression of transcription (Tse 
C. et al. 1998). Methylation of lysine 4 of histone H3 is linked to active genes, while 
methylation of H3/K is linked to a repressed state (Lachner M. et al. 2002). ChIP in 
combination with qPCR or microarray analysis could be used to study the 
modification status at the promoter and other regulatory elements of BCR-abl gene. 
This would allow to determine the role of histone modifications in the regulation of 
this gene, as well as to investigate on the activation or repression of the gene.  
                                                                                                                                     Perspectives 
Dr. Silvia Bono 
“Energy shortage regulates BCR-Abl expression in Chronic Myeloid Leukemia cells  
via transcriptional/post-transcriptional control”                                             50 
Further confirmation of the role of translational control in 
BCR-Abl expression  
 
The translation of mRNAs into polypeptides is carried out in ribosomes (80S), 
that in eukaryotes are composed of two subunits. The small subunit has a 
sedimentation value of 40S, whereas the large subunit of 60S. The mechanism of 
protein synthesis can be described as having four distinct phases: (1) initiation: the 
small ribosomal subunit binds to the mRNA, and upon selection of the initiator AUG 
codon, the large ribosomal subunit is recruited to form the translation-competent 80S 
(70S in prokaryotes) ribosome; (2) elongation: decoding of mRNA sequence, 
delivery of amino acids by aminoacyl-tRNAs and incorporation into the growing 
polypeptide chain via the formation of peptide bonds (3) termination: release of the 
polypeptide upon recognition of a stop codon on mRNA and (4) recycling of the 
ribosomes into free subunits that continue translation of other mRNAs. An 
experimental approach which is widely used to study structure/function of ribosomes 
and also to monitor the efficiency of mRNA translation is the use of sucrose 
gradients to separate free ribosomal subunits from translating ribosomes by velocity 
sedimentation. Because ribosomal subunits are larger than free mRNA protein 
complexes, this methodology can also separate the two populations from cellular 
extracts. In addition, translating mRNAs, which are bound to several ribosomes, 
forming polyribosomes, migrate with much larger fractions in sucrose gradients. The 
sedimentation velocity of polyribosomes depends on their size, which relates to the 
efficiency of translation of the corresponding mRNA. The larger the corresponding 
mRNA and the number of bound ribosomes, the higher the sedimentation velocity. 
Sedimentation of particles is monitored by measuring the absorbance of the fractions 
at 254 nm, which provides the so-called ‘polysome profile’. A typical polysome 
profile shows distinct peaks for the free ribosomal subunits (small 40S and large 
(60S), followed by the 80S ribosomes and heavier polyribosomes (Krokowski D. et 
al. 2011). 
So, to better understand whether the energy shortage causes BCR-Abl 
translational initiation inhibition, polysome profile technique could allow us to 
determine whether CML cells we used are able to form ribosomal dimers, 
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translationally active. In fact, if translation initiation is inhibited, an increased 
accumulation of free ribosomal subunits and non-translating monosomes and a 
decrease in the polyribosome pool should be obtained. On the contrary, sustained 
association of mRNAs with polyribosomes would be associated with efficient 
translation of the corresponding mRNAs. 
 
Determination of the possible role of other RNA binding 
proteins in response to energy shortage 
 
Post-transcriptional mechanisms are key determinants in the modulation of the 
expression of final gene products. AU-rich elements are frequently found within the 
3’ UTRs of mRNAs coding for proteins with roles in the immune system, growth and 
survival. Within this context, fundamental players are RNA-binding proteins. Their 
dysregulation can lead to disease (Pichon X. et al. 2012).  
As described above, RNA binding proteins are able to affect every aspect in the 
processing of transcripts, from alternative splicing, polyadenylation, and nuclear 
export to cytoplasmic localization, stability, and translation. Of interest is the fact 
that more than one RNA-binding protein can bind simultaneously the same mRNA; 
each protein is endowed with different properties, so that the balance of these 
interactions dictates the ultimate fate of the transcript, especially in terms of stability 
and rate of translation (Pascale A. et al. 2012). 
Since recent data demonstrated the involvement of different classes of RNA-
binding proteins in normal hematopoiesis and leukemogenesis (Baou M. et al. 
2011), we could investigate whether other AUBP are involved in the post-
transcriptional/translational control of BCR-Abl. If one or more AUBP were 
involved in BCR-Abl regulation, the next step would be silencing and 
overexpression of them, to confirm their role. 
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Potential miRNA involvment in BCR-Abl control during 
energy shortage conditions 
 
Micro RNA (miRNA) are small non-coding RNA molecules (22-24 nucleotides) 
that regulate gene expression via post-transcriptional mechanisms. Following binding 
to target sites in mRNA, miRNA can both repress translation and destabilize specific 
mRNA, although recent studies have indicated that the predominant form of 
regulation may be mRNA destabilisation (Stevens S.G. et al. 2013). 
A miRNA in its mature form can bind to the 3′-UTR of a target mRNA due to 
the partial sequence complementarity between the two (Lewis B.P. et al. 2005). 
Binding of a miRNA to its target triggers one or more of the following mechanisms 
of mRNA post-transcriptional inactivation: 1) mRNA cleavage, 2) inhibition of 
mRNA translation, or 3) mRNA deadenylation and rapid degradation. Of these 
mechanisms, miRNA-induced inhibition of translation primarily involves the 
prevention of targeted mRNA from undergoing translation initiation or elongation, 
without affecting the levels of mRNA expression (Zeng Y. et al. 2003). 
Recently, it was demonstrated the role of different miRNAs, including MIR150, 
MIR203, MIR328, MIR10A, MIR181A, MIR130 in CML, many of them directly 
correlated with BCR-abl transcript levels (Gordon J.E.A. et al. 2013).  
So, we could investigate the possible miRNA deregulation (up-regulation or 
down-regulation) during energy shortage (hypoxia or glucose starvation) and 
correlate these alterations to BCR-Abl down-regulation. We would use quantitative 
RT PCR-based methods to detect and quantify miRNA. These are also incorporated 
into higher throughput approaches including the widely used Taqman low density 
array system (Chen C. et al. 2005). Hybridization methods employ differing 
labelling strategies. One recently developed platform is the NanoString system where 
miRNA are counted directly, with minimal pre-amplification. This approach utilizes 
a barcoding system with sufficient diversity to allow discrimination between highly 
similar miRNA variants (Wyman S.K. et al. 2011). 
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Materials and Methods 
 
Cell cultures 
 
The human BCR-Abl positive K562 and KCL22 CML cell lines were obtained 
from ATCC (Rockville, MD, USA). Cells were cultured in RPMI 1640 medium 
(Gibco by Life Technologies, Carlsbad, CA, USA) supplemented with 10% heat-
inactivated foetal bovine serum (FBS), 2 mM L-glutamine, 50 units/mL penicillin 
and 50 µg/ml streptomycin (all from EuroClone, Paington, UK) with high D-glucose 
(4.5 g/L), at 37°C. In some experiments, we used RPMI 1640 medium without D-
glucose, supplemented as above. 
Experiments were performed with exponentially-growing cells, harvested from 
maintenance cultures subcultured in fresh medium 24 h before plating, and plated at 
3x105/mL. Incubation in normoxia (21% O2) with or without glucose was carried out 
in a conventional cell culture incubator in a 5% CO2, 95% air water-saturated 
atmosphere. Incubation in severe hypoxia (0.1% O2) was carried out in a Ruskinn 
Concept 400 anaerobic incubator, flushed with a preformed gas mixture (0.1% O2, 
5% CO2, 94.9% N2) and water-saturated. This incubator allows easy entry and exit of 
materials and sample manipulations without compromising the hypoxic environment. 
Viable cells were counted in a hemocytometer by trypan blue exclusion. 
 
Protein extraction, separation and Western blotting 
 
Cells were washed with ice-cold PBS containing 100 µM Na3VO4 and 
solubilized by incubating for 10 minutes at 95°C in Laemmli buffer (62.5 mM 
Tris/HCl, pH 6.8, 10% glycerol, 0.005% bromphenol blue, and 2% SDS). Lysates 
were clarified by centrifugation (14000g, 5 minutes, RT) and protein concentration in 
supernatants was determined by the BCA method.  
Whole cell extracts (50 µg/lane) were boiled for 10 minutes in the presence of 
100 mM 2-mercaptoethanol, separated by SDS-PAGE in 9% polyacrylamide 
minigels, and then transferred onto PVDF membranes (Merck Millipore, Billerica, 
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MA, USA) by electroblotting. Membranes were blocked in 1:1 Odyssey blocking 
buffer (OBB)/phosphate-buffered saline (PBS) for 1 hour at RT and incubated with 
primary antibody in 1:1 PBS-0,1% Tween (T-PBS)/OBB overnight at 4°C (LI-COR® 
Biosciences, Lincoln, NE, USA).  
Primary antibodies used were: rabbit anti-phospho-c-Abl (Tyr245) (from Cell 
Signaling Technology, Danvers, MA, USA), mouse anti-α-Tubulin, mouse anti-
Vinculin (from Sigma Aldrich, St. Louis, MO, USA), rabbit anti-c-Abl, mouse anti-
HuR (from Santa Cruz Biotechnology, S. Cruz, CA, USA).  
Secondary anti-IgG antibodies were IRDye®800CW- or IRDye®680-conjugated 
(LI-COR®). Antibody-coated protein bands were visualized by the Odyssey Infrared 
Imaging System Densitometry (LI-COR®) and images analyzed by Odyssey software 
to measure the mean fluorescence intensity (MFI) value of the area selected for each 
band. A background measurement was also taken. 
 
RNA isolation and quantitative Real Time RT-PCR 
 
For each experimental condition, the cells were washed once with ice-cold PBS 
and total RNA was extracted using TRIzol (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturerʼs instructions. Residual DNA was removed by 
treatment with 5 units of DNase I (Roche Diagnostics, Lewes, UK) at RT for 15 
minutes followed by inactivation at 65°C for 10 minutes. RNA concentration 
(µg/µL) was determined by spectrophotometric reading at 260 nm wavelength, and 
the purity of RNA was determined by calculating the ratio of absorbance at 260/280 
nm. After, determination of quality and integrity of total RNA was assessed on 2% 
agarose gels. 
Five hundred nanograms of total RNA were reverse-transcribed to cDNA using 
the ImProm-IITM Reverse Transcription System (Promega, Madison, WI, USA) 
according to the manufacturerʼs protocol.   
Quantitative Real-Time PCR analysis of the BCR-ABL p210 transcript (b2a2 for 
the KCL22 cells, b3a2 for the K562 cells) was performed using the Applied 
Biosystems 7500 Fast Real-Time PCR System (Life Technologies) under the 
following conditions: Hot Start Activation at 95°C for 2 minutes (1 Cycle), 
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Denaturation at 95°C for 15 seconds, Annealing at 56°C for 20 seconds, and 
Extension at 60°C for 40 seconds (40 Cycles), Dissociation at 60-95°C (1 Cycle). 
The PCR mixture consisted of 2X GoTaq qPCR Master Mix (Promega, Madison, 
WI, USA), which includes GoTaq® Hot Start Polymerase polymerase, a new 
fluorescent DNA-binding dye that exhibits greater fluorescence enhancement upon 
binding to dsDNA than SYBR Green I, dNTPs, and PCR buffer. To this were added 
forward and reverse primers, and cDNA of samples in a total volume of 20μl. The 
amplification of a housekeeping gene, GAPDH or 18S rRNA (data not showed), was 
used to normalize the efficiency of cDNA synthesis and the amount of RNA applied. 
Primers (from Integrated DNA Technologies, Coralville, IA, USA) were: 
BCR-abl forward primer: 5’-GGAGCAGCAGAAGAAGTGTTT-3’,  
BCR-abl reverse primer: 5’-TGGGTCCAGCGAGAAGGTTTT-3’,  
GAPDH forward primer: 5’-AACAGCCTCAAGATCATCAGCAA-3’,  
GAPDH reverse primer: 5’-TCTGGGTGGCAGTGAT-3’,  
18S forward primer: 5’- CGGCTACCACATCCAAGGAA-3’,  
18S reverse primer: 5’- GCTGGAATTACCGCGGCT-3’. 
Experiments were repeated with cDNA from at least 3 independent experiments, 
using a minimum of triplicates for each sample. Negative controls were performed 
with samples in which RNA templates in the reaction were replaced by nuclease-free 
water.  
Based on the cycle threshold method, as recommended by the manufacturer, the 
observed measurements of the BCR-abl fusion transcripts and of the internal 
standard, GAPDH or 18S rRNA, in the tested samples were calculated against a 
standard curve previously obtained using serially diluted samples prepared from 
K562 and KCL22 leukemia cells. The rationale for the need of such a normalization 
was that PCR efficiencies varied from sample to sample. Therefore, the actual 
quantities of BCR-abl and GAPDH or BCR-abl and 18S rRNA transcripts in the 
tested samples were adjusted accordingly.  
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Analysis of mRNA stability following inhibition of 
transcription by actinomycin D 
 
The half-life of BCR-abl mRNA stability was determined by treating K562 and 
KCL22 cells with Actinomycin D (Sigma-Aldrich).  Cultures were incubated in 
normoxia or in hypoxia for 24 h, and then Actinomycin-D was added into the growth 
medium (5µg/mL) to block transcription. During the following 8 h, cells were 
harvested every two hours, and total RNA was extracted using TRIzol. The amounts 
of BCR-abl mRNA and GAPDH mRNA at each time point were determined by 
quantitative Real Time-PCR and mRNA stability among hypoxic and normoxic 
cultures compared.  
 
Luciferase activity assay 
 
The luciferase constructs, pGL3/BCR, containing the BCR promoter, and 
pGL3/empty vectors were kindly provided by professor Carlo Gambacorti Passerini 
(Unità di Ricerca Clinica-Ematologia, Azienda Ospedaliera San Gerardo/Università 
di Milano Bicocca, Monza, Italy).  
K562 cells were transiently co-transfected with 1 μg pGL3-luc/BCR promoter 
plasmid or pGL3-luc/empty construct using LipofetamineTM 2000 (Life 
Technologies). The most efficient transfection was obtained using a LipofectamineTM 
2000 to DNA ratio of 2:1 (μl:μg). pGL4 plasmid (0.1 μg) (Promega) expressing 
Renilla luciferase was used to normalize for transfection efficiency. After six hours 
from transfection, cells were diluited at 3x105/mL and incubated in normoxia or 
hypoxia until the time of analysis in luminescence.  
After 24 h, 48h, and 72h cells were washed, and a Dual-Glo™ Luciferase Assay 
System (Promega) was used to determine relative luciferase activity according to the 
manufacturer's protocol. Results were expressed as the ratio of Firefly 
luciferase/Renilla luciferase at equal amounts of protein. Each experiment represents 
the mean of three replicates and was repeated at least three times. 
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Analysis of protein stability by Cycloheximide assay 
 
To test BCR-Abl protein stability, K562 and KCL22 cells were incubated in 
normoxia w/ glucose or incubated in normoxia w/o glucose or hypoxia w/ glucose 
for 24h. Cycloheximide (Sigma-Aldrich) was added at a final concentration of 50µM 
to block new protein synthesis and cells were harvested after 24, 48, or 72h. Cells 
were lysed and the expression of BCR-Abl protein was analyzed by Western 
blotting. Signals detected on blots were quantified by densitometry, and the data 
were plotted to determine protein half-life. 
 
The Culture Repopulating Ability (CRA) assay 
 
This assay estimates the culture repopulating potential of normal or leukemic 
hematopoietic cells undergone a selection treatment in a primary liquid culture (LC1) 
by means of their transfer in fresh medium to non-selective conditions in a growth-
permissive secondary culture (LC2) and the measure of its repopulation following a 
further incubation therein. Before being replated into LC2, cells selected in LC1 
were counted, centrifuged, and resuspended in fresh medium. Cell subsets rescued 
from LC1 at different times repopulate LC2 with different kinetics, the time 
necessary to reach the peak of LC2 repopulation reflecting the hierarchical level of 
stem/progenitor cells enriched in LC1.  
   The CRA assay is a non-clonogenic assay capable to reveal in vitro stem cells 
endowed with marrow-repopulating ability in vivo. The adaptation of CRA assay to 
leukemia cell populations enabled to detect different subsets of leukemia stem or 
progenitor cells. 
 
Statistical analysis 
 
All data were expressed as Mean ± standard deviation (SD) of three or more 
indipendent experiments. Differences were tested by the Student's t-test, considering 
p-values ≤ 0.05 and ≤ 0.01 statistically significant. 
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The CRA and MRA assays. Schematic representation of CRA (in vitro) and MRA (in vivo) assays 
and their relationship.  
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